Analyst firms · Leerink Partners · EXAS

Leerink Partners EXAS price target and rating history

Exact Sciences Corporation (EXAS) · Health Care

Leerink Partners rates Exact Sciences Corporation (EXAS) Outperform with a $130 price target, as of its latest action on Feb 23, 2022. It has published 3 rating actions on EXAS since July 2021, including 0 upgrades and 0 downgrades.

Current rating
Outperform
Price target
$130
Median target, all firms
Too few
Actions on EXAS
3

Leerink Partners price target on EXAS

$160$145$13020222023202420252026
Leerink Partners price target on EXAS, each point a stated target, July 2021 to February 2022.

Every Leerink Partners rating on EXAS

How other firms rate EXAS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
MizuhoNeutral$105Jan 20, 2026
Evercore ISIIn-line$105Jan 5, 2026

Questions about Leerink Partners and EXAS

What is Leerink Partners's price target for EXAS?
Leerink Partners's latest stated price target for Exact Sciences Corporation (EXAS) is $130, from its action on Feb 23, 2022.
What is Leerink Partners's rating on EXAS?
Leerink Partners rates EXAS Outperform, a bullish rating, as of Feb 23, 2022.
When did Leerink Partners last change its view on EXAS?
On Feb 23, 2022, Leerink Partners cuts its price target to $130 from $140, keeps Outperform.

More EXAS rating histories

All Leerink Partners ratingsEXAS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.